Chenyang Zhan1, David Ruohoniemi2, Krishna P Shanbhogue3, Jason Wei2, Theodore H Welling4, Ping Gu5, James S Park6, Nabil N Dagher7, Bedros Taslakian1, Ryan M Hickey8. 1. Division of Vascular Interventional Radiology, Department of Radiology, New York City, New York. 2. New York University Langone Health, NYU School of Medicine, New York City, New York. 3. Division of Abdominal Imaging, Department of Radiology, NYU Langone Health, NYU School of Medicine, New York City, New York. 4. Perlmutter Cancer Center and Department of Surgery, NYU Langone Health, NYU School of Medicine, New York City, New York. 5. Department of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York. 6. Hepatology Section, Division of Gastroenterology, Department of Medicine, NYU Langone Health, NYU School of Medicine, New York City, New York. 7. Transplant Institute, NYU Langone Health, NYU School of Medicine, New York City, New York. 8. Division of Vascular Interventional Radiology, Department of Radiology, New York City, New York. Electronic address: ryan.hickey@nyulangone.org.
Abstract
PURPOSE: To investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A-B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses. RESULTS: The median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6-11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1-3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9-23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6-26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2-7.2), and progression-free survival was 5.7 months (95% CI, 4.3-7.1). CONCLUSIONS: Radioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy.
PURPOSE: To investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A-B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses. RESULTS: The median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6-11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1-3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9-23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6-26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2-7.2), and progression-free survival was 5.7 months (95% CI, 4.3-7.1). CONCLUSIONS: Radioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy.
Authors: Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias Journal: Oncologist Date: 2021-01-02
Authors: Natally Horvat; Ana I de Oliveira; Brunna Clemente de Oliveira; Jose A B Araujo-Filho; Maria El Homsi; Ahmed Elsakka; Raazi Bajwa; Guilherme L P Martins; Khaled M Elsayes; Marcos R Menezes Journal: Radiographics Date: 2022-10 Impact factor: 6.312
Authors: Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-17 Impact factor: 10.057
Authors: Daniel Brown; Henry Krebs; Jayson Brower; Ryan O'Hara; Eric Wang; Kirubahara Vaheesan; Liping Du; Lea Matsuoka; Donna D'Souza; Daniel Y Sze; Jafar Golzarian; Ripal Gandhi; Andrew Kennedy Journal: J Gastrointest Oncol Date: 2021-04